Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITPR3 | Q14573 | 7/20 | 0.56 |
| ▸ | ITPR2 | Q14571 | 3/20 | 0.54 |
| ▸ | ITPR1 | Q14643 | 3/20 | 0.54 |
| ▸ | INPPL1 | O15357 | 1/20 | 0.54 |
| ▸ | AKT1 | P31749 | 1/20 | 0.54 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.52 |
| ▸ | INPP5A | Q14642 | 3/20 | 0.48 |
| ▸ | FDPS | P14324 | 1/20 | 0.45 |
| ▸ | BLM | P54132 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29869445 | 1.00 | ITPR3 (0.56) | ITPR3ITPR2ITPR1INPPL1AKT1 | |
| SCHEMBL6710149 | 1.00 | ITPR3 (0.56) | ITPR3ITPR2ITPR1INPPL1AKT1 | |
| SCHEMBL3498450 | 1.00 | ITPR3 (0.56) | ITPR3ITPR2ITPR1INPPL1AKT1 | |
| SCHEMBL29602097 | 1.00 | ITPR3 (0.56) | ITPR3ITPR2ITPR1INPPL1AKT1 | |
| SCHEMBL30629453 | 1.00 | ITPR3 (0.56) | ITPR3ITPR2ITPR1INPPL1AKT1 | |
| SCHEMBL6708568 | 1.00 | ITPR3 (0.56) | ITPR3ITPR2ITPR1INPPL1AKT1 | |
| SCHEMBL3500008 | 1.00 | ITPR3 (0.56) | ITPR3ITPR2ITPR1INPPL1AKT1 | |
| SCHEMBL30713458 | 1.00 | ITPR3 (0.56) | ITPR3ITPR2ITPR1INPPL1AKT1 | |
| Scyllitol SCHEMBL5997336 | 0.91 | ITPR3 (0.64) | ITPR3ITPR2ITPR1INPPL1AKT1 | |
| SCHEMBL4343592 | 0.91 | ITPR3 (0.74) | ITPR3ITPR2ITPR1INPPL1AKT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 73 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250197875-A1 | ENGINEERED PLANTS HAVING MODIFIED INOSITOL PYROPHOSPHATES | VIRGINIA TECH INTELLECTUAL PROPERTIES, INC. | 2025-06-19 | — | — | US | claimed |
| US-20250127768-A1 | THERAPEUTIC TARGETING OF INOSITOL PYROPHOSPHATE SYNTHESIS IN CANCER | THE BROAD INSTITUTE, INC. (US) | 2025-04-24 | — | — | US | claimed |
| WO-2024006972-A1 | THERAPEUTIC TARGETING OF INOSITOL PYROPHOSPHATE SYNTHESIS IN CANCER | THE BROAD INSTITUTE, INC. (US) | 2024-01-04 | — | — | WO | claimed |
| WO-2023178098-A2 | ENGINEERED PLANTS HAVING MODIFIED INOSITOL PYROPHOSPHATES | VIRGINIA POLYTECHNIC INSTITUTE AND STATE UNIVERSITY (US) | 2023-09-21 | — | — | WO | claimed |
| CN-116298235-A | Serum metabolism biomarker for diagnosing or monitoring breast cancer and screening method thereof | 哈尔滨医科大学 | 2023-06-23 | — | — | CN | claimed |
| US-20250346572-A1 | NON-ACID INHIBITORS OF INOSITOL HEXAKISPHOSPHATE KINASE (IP6K) AND METHODS OF USE THEREOF | LIEBER INST INC (US) | 2025-11-13 | — | — | US | disclosed |
| US-20250197396-A1 | COMPOUNDS FOR INHIBITING INOSITOL HEXAKISPHOSPHATE KINASE (IP6K) AND METHODS OF USE THEREOF | LIEBER INSTITUTE, INC. | 2025-06-19 | — | — | US | disclosed |
| US-20250197875-A1 | ENGINEERED PLANTS HAVING MODIFIED INOSITOL PYROPHOSPHATES | VIRGINIA TECH INTELLECTUAL PROPERTIES, INC. | 2025-06-19 | — | — | US | disclosed |
| US-20250127768-A1 | THERAPEUTIC TARGETING OF INOSITOL PYROPHOSPHATE SYNTHESIS IN CANCER | THE BROAD INSTITUTE, INC. (US) | 2025-04-24 | — | — | US | disclosed |
| EP-4539838-A1 | NON-ACID INHIBITORS OF INOSITOL HEXAKISPHOSPHATE KINASE (IP6K) AND METHODS OF USE THEREOF | Lieber Institute, Inc. (US) | 2025-04-23 | — | — | EP | disclosed |
| US-20240271122-A1 | METHODS FOR CODON OPTIMIZATION AND USES THEREOF | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2024-08-15 | — | — | US | disclosed |
| US-20240226165-A1 | Methods of Producing Improved Immune Cell Populations | Prescient Therapeutics Ltd (AU) | 2024-07-11 | — | — | US | disclosed |
| EP-1471934-A2 | KINASES INVOLVED IN THE REGULATION OF ENERGY HOMEOSTASIS | DeveloGen Aktiengesellschaft für entwicklungsbiologische Forschung (DE) | 2004-11-03 | — | — | EP | disclosed |
| US-20040110939-A1 | Complementary DNAs encoding proteins with signal peptides | GENSET, S.A. (FR) | 2004-06-10 | — | — | US | disclosed |
| US-20040029130-A1 | Drug screening systems and assays | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2004-02-12 | — | — | US | disclosed |
| WO-2003066087-A2 | KINASES INVOLVED IN THE REGULATION OF ENERGY HOMEOSTASIS | DEVELOPGEN AKTIENGESELLSCHAFT FÜR ENTWICKLUNGSBIOLOGISCHE FORSCHUNG (DE) | 2003-08-14 | — | — | WO | disclosed |
| US-20030144490-A1 | Extended cDNAs for secreted proteins | SERONO GENETICS INSTITUTE S.A. (FR) | 2003-07-31 | — | — | US | disclosed |
| US-6573068-B1 | Purified and isolated polypeptide of given amino acid sequence; cDNA can be used to express it or to obtain antibodies that specifically bind to it | GENSET, S. A. (FR) | 2003-06-03 | — | — | US | disclosed |
| EP-1283903-A1 | DRUG SCREENING SYSTEMS AND ASSAYS | Cancer Research Technology Limited (GB) | 2003-02-19 | — | — | EP | disclosed |
| WO-2001090404-A1 | DRUG SCREENING SYSTEMS AND ASSAYS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2001-11-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250346572-A1 | NON-ACID INHIBITORS OF INOSITOL HEXAKISPHOSPHATE KINASE (IP6K) AND METHODS OF USE THEREOF | IP6K1, IP6K2, IP6K3 | ITPR3 186/4885ITPR2 173/4885ITPR1 139/4885 |
| US-20030144490-A1 | Extended cDNAs for secreted proteins | DNASE1L3, DNAJC10, PRSS12 | ITPR3 4294/4885ITPR2 4489/4885ITPR1 4573/4885 |
| US-20250127768-A1 | THERAPEUTIC TARGETING OF INOSITOL PYROPHOSPHATE SYNTHESIS IN CANCER | PPIP5K2, IP6K1, IP6K2 | ITPR3 63/4885ITPR2 59/4885ITPR1 37/4885 |
| US-20250197396-A1 | COMPOUNDS FOR INHIBITING INOSITOL HEXAKISPHOSPHATE KINASE (IP6K) AND METHODS OF USE THEREOF | IP6K1, IP6K2, IP6K3 | ITPR3 172/4885ITPR2 152/4885ITPR1 127/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.